Engineering personalized
neoantigen vaccine
revolution

nanosferic structure
Enabling precision oncology.
High-density tumor antigen presentation.
Targeting T cell and B cell immune response.
Off-the-shelf scaffold.
Melanoma as a prime target.
Neoantigen vaccines

nanoSFERICTM combines advances in protein science, data science, and manufacturing to make personalized cancer vaccines more accessible. It also enables researchers and clinicians to evaluate and refine treatments more rapidly than ever before. Ultimately, nanoSFERICTM aims to bring powerful, individualized immunotherapy to more patients worldwide.

lab
Technology

We have developed nanoSFERICTM, a proprietary self-assembling protein nanoparticle platform with superior immunogenicity

The assembled nanoSFERICTM particles form immunogenic rings with repeating target epitopes in eukaryotic and prokaryotic expression systems.

The planar display of repeating epitopes promotes B cell receptor cross-linking, boosting B cell activation and antigen-specific antibody production.

Platform diversity

Infectious diseases

Oncology

Veterinary

Antibacterial

Immunomodulatory

Diagnostics

Pipeline
pipeline
Services

R&D and manufacturing services

At Sferogen, we have developed a tailored manufacturing pipeline to support clinical-grade vaccine purity, paving the way to the clinic.

 

We offer platform-independent development services for recombinant proteins, mRNA, and other modalities.

Publications    
The team

Our multidisciplinary team brings together experts who accelerate the journey from discovery to clinic.

Urban BEZELJAK

Urban BEZELJAK

PhD, CEO and
Chief R&D

At Sferogen, Urban is the leading inventor of the proprietary nanoSFERICTM vaccine platform, leading the research and design of this versatile technology. Urban is a molecular biology and biochemistry expert with experience in mammalian and insect cell culture expression technology. He earned his Master's degree in biochemistry at the University of Ljubljana (Slovenia) and holds a PhD from the Institute of Science and Technology Austria.
Alexander JERMAN

Alexander JERMAN

MD, CMO,
nephrologist

At Sferogen, Alexander is working closely with the advisory committee to identify new targets, plan preclinical trials and pave the way for the first-in human trials. Alexander is a scientist-physician with experience in immunology, nephrology and blood-purification. He holds an M.D. with honors from the University of Ljubljana and is a certified nephrologist.
Uroš FERJANČIČ

Uroš FERJANČIČ

MSc, COO,
tech transfer specialist

As chief operating officer at Sferogen, Uroš is responsible for planning and implementing of the company's daily operational functions, including management of purchasing, accounting (ERP, IT, IP), intellectual property, infrastructure, marketing, business planning, and branding. With over two decades of experience in sales, marketing, and manufacturing processes, Uroš brings a specialized interest in technology transfer to the role.
Matjaž PETERKA

Matjaž PETERKA

PhD,
Business Development

Matjaž is co-founder of Sferogen, guiding the long-term research strategy and overseeing business development activities. With over 20 years of leadership experience in the biotech industry, Matjaž has a proven track record in multifaceted roles, including extensive expertise in the manufacturing of viral vaccines, and bioprocess control.
Our story

Sferogen was established in 2022 as a spin-off from COBIK, a research and development organization in the field of biotechnology.

eVLP

We developed an enveloped virus-like particle (eVLP) lead COVID-19 vaccine candidate, nSfCoVac, using a high-throughput insect cell line. This vaccine consists of three main SARS-CoV-2 structural proteins. We developed innovative purification steps to yield highly pure virus-like particles with the intended morphology. Preclinical studies in a mouse model showed an immune response comparable to that of approved vaccines.

nanoSFERIC

We have developed an innovative recombinant nanoSFERICTM platform that has a number of key features, including a modular design, fast antigen switching, and scalable production. In a preclinical model, our lead vaccine candidate demonstrated a strong immune response after single dose.

Contact

Work with us

Our aim is to turn most innovative ideas into reality. That is why we are constantly challenging concepts, seeking new ideas and looking for bold, pioneering partners.

We believe that next decade will witness paradigm shifts in our understanding of immune system and systems biology. This, in concert with current pace of innovation in biotechnology will enable the design of novel, better and safer vaccines for global health. On the other side, our ability to indentify patient-specific characteristics in oncology will exponentially expand the area of personalized medicine. This will bring together the multiple layers of knowledge and expertise within a One Health apprach.

We are looking for innovative talents in research, biotechnology, clinical medicine, and regulatory affairs to help us achieve our ambitious goals.

Write or call us on:

+386(0)40 54 84 64
info@sferogen.com